The size of the global in-vitro toxicology testing market is expected to reach USD 79004.6 Million by 2032 from USD 27400.6 Million in 2024, growing at a CAGR of 14.16% from 2024 to 2032.
Recently, regulatory agencies' validation and acceptance of in vitro toxicology testing methods are increasing at a lucrative rate, boosting the market. In several countries, government regulations mandate that animal geno-toxicology testing be performed before marketing the products for certain consumer items, genetically modified foods, vaccines, devices, drugs, industrial chemicals, and pesticides. Furthermore, technological advancements to replace animals for toxicological testing have spurred in vitro testing models. In addition, increasing awareness of toxicity testing studies, expanding health consciousness amongst individuals, and improving economic status in emerging nations, the existence of favorable regulatory authorities for toxicology testing using in-vitro tests drives the market's growth during the forecast period.
However, scarcity of in-vitro models to detect immunostimulants & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological advancements limiting the use & decreasing adoption rate are the significant factors restraining the growth of the in-vitro toxicology testing market. In addition, strict government regulations for the in vitro toxicology testing market are anticipated to limit the market growth. Furthermore, the inability of in vitro models to regulate immune stimulation and autoimmunity is also expected to be a significant constraint for the global in-vitro toxicology testing market. Furthermore, there is a requirement for skilled professionals, such as researchers and technicians, to perform experiments. Therefore, a lack of knowledge about these technologies and inadequate staff are expected to slow the market down.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Product, Type, Toxicity, Endpoints and tests, Method, Technology, Industry, and Region. |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Market Leaders Profiled |
Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg) |
Based on the product, the assay segment is estimated to command the largest share of the global in-vitro toxicology testing market during the forecast period. This segment is strongly driven by an increasing number of in-vitro tests being performed worldwide, which leads to the recurrent purchase of reagents and other labware.
Based on the type, the ADME segment is predicted to stand top in leading max shares in the market during the forecast period due to a growing number of early stages in vitro ADME examining tests in preventing failure.
Based on toxicity endpoints & tests, the systemic toxicity segment is estimated to command the largest share of the global in-vitro toxicology testing market as multiple organ development with assumed blood flow for assessing systemic toxicity drives the segment growth.
The dermal toxicity segment is next in line with a considerable growth rate throughout the forecast period. Dermal toxicology is simple, easy, reliable, and cost-effective. Moreover, advancement related to dermal toxicity and risk assessment tools is projected to surge the segment growth globally.
The cell culture technology segment is projected to dominate the market globally based on technology. It is an excellent model for screening toxic effects as it offers consistent samples and reproducible results. Moreover, it supports the tissue-specific function, which urges cell proliferation.
However, the OMICS technologies segment is projected to have the highest CAGR during the forecast period as it provides personalized toxicology data, understanding the toxicity of nano-sized materials.
Based on industry, the cosmetics & household products industry accounted for the largest market share of the global in-vitro toxicology testing market by industry in 2023.
However, the pharmaceutical segment is expected to dominate the market during the forecast period as the rise influences this segment in support of the government. In addition, launching innovative drugs with advanced technologies mainly surges the demand for this segment.
The chemical industry is expected to witness lucrative growth over the forecast period due to continuous toxicity profiling and safety assessment advancements.
Globally, the In-Vitro Toxicology Testing Market in Europe is estimated to account for 32.5% of the global in-vitro toxicology testing market in 2023 and Germany is anticipated to dominate and have the largest share in this region. France is expected to grow with the highest CAGR over the forecast period.
The In-Vitro Toxicology Testing Market in North America is anticipated to dominate the global IVTT market over the forecast period. Support from government regulations and the adoption of technological advancements are propelling the market's demand. The U.S. is leading the market in this region because of genetics and genetic screening approaches and the emergence of a new 3D cell culture approach.
The In-Vitro Toxicology Testing Market in Asia-Pacific is expected to grow at the highest CAGR of 16.10% during the forecast period. The growth is attributed to the emergence of CROs for outsourcing toxicology-relevant research projects and increasing consumer awareness of product safety.
The In-Vitro Toxicology Testing Market in Latin America is expected to have a commendable share in the IVTT. With an increasingly aging population, research and development investments influence cell culture research. Brazil is leading the IVTT market.
The In-Vitro Toxicology Testing Market in the Middle East & Africa region is expected to have minimal growth in the IVTT market due to the demand for advanced technologies and the appearance of various analytical methods over bioinformatics and biotechnology.
Noteworthy companies operating in the global in-vitro toxicology testing market include Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.
By Product
By Type
By Toxicity Endpoints & Tests
By Technology
By Method
By Industry
By Region
Frequently Asked Questions
The global in-vitro toxicology testing market size was valued at USD 24002 million in 2023.
Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Eurofins Scientific, and Charles River Laboratories International are some of the notable companies in the in-vitro toxicology testing market.
The growing need for standardization and validation of testing methods, high costs of some testing technologies, and limitations in the ability of in-vitro testing to fully replicate the complexity of the human body primarily challenge the in-vitro toxicology testing market growth.
The growing number of regulatory requirements for safety testing of chemicals, rising public concern over animal testing, and advancements in in-vitro testing technologies are majorly boosting the growth of the in-vitro toxicology testing market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region